Benjamin Zev Leder, MD

Massachusetts General Hospital
Endocrine Unit

Biographical Sketch:
Dr. Benjamin Z. Leder is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician and clinical investigator in the Endocrine Unit at Massachusetts General Hospital. Dr. Lederís major research endeavors include aiming to define the role that gonadal steroids play in regulating bone metabolism through smaller physiology-based studies, clinical trials, and epidemiologic studies. In parallel, his research also focuses on developing novel therapeutic approaches to treat osteoporosis in men and women. He has been involved in the early studies of the RANK-ligand inhibitor- denosumab in men undergoing androgen deprivation treatment as well as numerous studies assessing the efficacy of combination therapy for osteoporosis in both men and women. His recent study assessing the effects of teriparatide in combination with denosumab in postmenopausal osteoporosis was the first to show an additive effect of combined antiresorptive and anabolic therapy in humans. Dr. Lederís is the medical director of the Mass General Hospital Endocrine Associates and his clinical practice focuses on osteoporosis and metabolic bone disease, with a special interest in male osteoporosis.
Male Osteoporosis
M24 Male Osteoporosis
S57 Challenges and Controversies in Bisphosphonate Therapy
S57-3 Anabolic Therapy in the Context of Antiresporptive Agents